P2.12-07 Utility of Stereotactic Body Radiotherapy in Pulmonary Carcinoid Tumors

Abstract

Pulmonary carcinoid (PC) tumors are rare malignant neoplasms, accounting for approximately 2% of all lung cancers. While most patients with PC undergo surgical resection, some patients either decline surgery or are not surgical candidates. Stereotactic body radiotherapy (SBRT) is primarily used in patients with early stage, inoperable non-small cell lung cancer or patients who refuse surgery. We sought to determine the role of SBRT in patients with PC. The records of all patients with PC seen at our clinic were retrospectively reviewed. Demographics, pathologic characteristics, and treatment data were collected. Only patients meeting the World Health Organization criteria for typical and atypical carcinoids were included. Radiographic evaluation of all patients was performed at 3-month intervals. Of the 251 patients with PC who were retrospectively reviewed, 3 patients were identified who underwent SBRT at our institution. All patients were female with a median age of 72 years. All patients received SBRT consisting of 50 Gy over 5 fractions. Median follow up time was 7 months. Median decrease in tumor size following SBRT was 29%. No adverse events from SBRT were reported. Our study demonstrates that SBRT is safe and feasible in patients with PC tumors. SBRT may represent a treatment option in patients with PC who are deemed inoperable due to comorbid conditions or decline surgery. Larger studies are needed to further determine the role of SBRT in PC.